Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists

US11292783B2 · kind B2 · utility

Assignee

• Research Triangle Institute · US

Inventors

• Frank Ivy Carroll · Durham, US
• Chad M. Kormos · Apex, US
• Pauline Wanjiku Ondachi · Raleigh, US
• Scott P. Runyon · Morrisville, US
• Hernan A. Navarro · Chapel Hill, US
• James B. Thomas · Efland, US
• S. Wayne Mascarella · Hillsborough, US

Key dates

• Filing date: Sep 15, 2017
• Grant date: Apr 5, 2022
• Expiry date: Nov 9, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/08
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Potent opioid receptor antagonists of formula (I) and their use as pharmacotherapies for treating depression, anxiety, schizophrenia, eating disorders, and addiction to cocaine, methamphetamine, nicotine, alcohol, and opiates are disclosed. More specifically, the disclosure provides potent and selective kappa opioid receptor antagonist compounds, pharmaceutical compositions of those compounds and uses of those compounds to ameliorate or treat addictions, eating disorders, etc.